|
|Section2= |Section3= }} Mertansine refers to the thiol-containing maytansinoid DM1, which for therapeutic purposes is attached to a monoclonal antibody through reaction of the thiol group with a linker structure to create an antibody-drug conjugate (ADC). Experimental ADCs with this design include lorvotuzumab mertansine. ==Mechanism of action== Mertansine is a tubulin inhibitor, meaning that it inhibits the assembly of microtubules by binding to tubulin (at the rhizoxin binding site).〔National Cancer Institute: (Definition of Maytansine )〕 The monoclonal antibody binds specifically to a structure (usually a protein) occurring in a tumour, thus directing mertansine into this tumour. This concept is called targeted therapy. 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Mertansine」の詳細全文を読む スポンサード リンク
|